Oslo, Norway, 5 May 2026: Reference is made to the stock exchange announcement
made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the
resolution by the extraordinary general meeting to decrease the share capital of
the Company by NOK 222,800,997, from NOK 223,920,600 to NOK 1,119,603, through a
reduction of the nominal value of the shares by NOK 49.75, from NOK 50 to NOK
0.25.

The resolution was published by the Norwegian Register of Business Enterprises
on 22 January 2026 and followed by a six-week creditor notice period, which was
completed without creditor objections.

The share capital decrease has today been registered as completed by the
Norwegian Register of Business Enterprises. Following the share capital
decrease, the share capital of the Company is NOK 1,119,603, divided into
4,478,412 shares, each with a nominal value of NOK 0.25.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: IR@oncoinvent.com (soug@oncoinvent.com)

This information is subject to the disclosure requirements pursuant to Euronext
Oslo Rule Book II for companies listed on Oslo Børs and Section 5-12 of the
Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is developing Radspherin[®], a receptor-independent alpha radiation
therapy that leverages the unique anatomy of the abdominal cavity to destroy
residual micrometastases using a single, highly localized dose of alpha
radiation. The initial clinical focus is treatment of ovarian and colorectal
cancer patients after surgical removal of the primary tumor and visible
metastases in the peritoneum, the thin membrane lining the abdominal cavity and
covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the
peritoneal cavity, keeping patients disease-free for longer than the current
standard of care and thereby also impacting overall survival. It is broadly
applicable to any cancer that spreads to the peritoneum, e.g. ovarian,
colorectal, and gastric cancers. Radspherin[®] stands out for its simplicity,
excellent safety profile, and seamless integration into existing surgical
workflows. Oncoinvent's product is easy to use, avoids systemic delivery and
significant toxicity. It is also differentiated in being simple to manufacture,
scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers,
are highly promising, showing an excellent safety profile and meaningful signals
of efficacy. Interim data from an ongoing, randomized, controlled phase 2
ovarian cancer trial is expected in 2026. With cost-effective manufacturing,
blockbuster potential, active pharma partnership momentum, plus strong
endorsements from leading experts, Oncoinvent is built for scale and commercial
success, and is set to become the new standard for post-surgical cancer care.
The Company was founded by the originators of Algeta and Xofigo (acquired by
Bayer).